SCHEMBL771339

SCHEMBL771339

O=C(CCNC(=S)Nc1ccccc1)N1CCCC2CCCCC21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.60
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
HSD11B1 P28845 5/20 0.52
HSD17B1 P14061 1/20 0.48
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
ABAT P80404 1/20 0.43
GAA P10253 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
FKBP1A P62942 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771583 0.92 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AHSD11B1HSD17B1
SCHEMBL770221 0.88 NPC1 (0.63) SMN1; SMN2NPC1RAB9AHSD11B1HSD17B1
SCHEMBL770950 0.85 NPC1 (0.66) SMN1; SMN2NPC1RAB9AHSD11B1HSD17B1
SCHEMBL770953 0.85 ALOX12 (0.48) SMN1; SMN2NPC1RAB9AHSD11B1KMT2A
SCHEMBL770367 0.84 NPC1 (0.46) SMN1; SMN2NPC1RAB9AHSD11B1HSD17B1
SCHEMBL770259 0.81 HSD11B1 (0.59) SMN1; SMN2NPC1RAB9AHSD11B1HSD17B1
SCHEMBL770799 0.81 DPP4 (0.60) SMN1; SMN2NPC1RAB9AHSD11B1HSD17B1
SCHEMBL771767 0.81 NPC1 (0.59) SMN1; SMN2NPC1RAB9AHSD11B1HSD17B1
SCHEMBL770331 0.80 KMT2A (0.43) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL771521 0.79 NPC1 (0.57) SMN1; SMN2NPC1RAB9AHSD11B1HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3653/4885NPC1 97/4885RAB9A 2187/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3637/4885NPC1 104/4885RAB9A 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.